Flavivirus Cross-priming Potential of IMOJEV (FlaviPrime)
Primary Purpose
Japanese Encephalitis
Status
Completed
Phase
Not Applicable
Locations
United Kingdom
Study Type
Interventional
Intervention
IMOJEV
Sponsored by
About this trial
This is an interventional diagnostic trial for Japanese Encephalitis
Eligibility Criteria
Inclusion Criteria:
- A male or female adult between 18 and 70 years of age at consent.
- Written and informed consent obtained from participant and agreement of participant to comply with the requirements of the study
- Able to attend regularly to donate study blood samples for the duration of the study (8 weeks), no planned re-location or travel to a flavivirus endemic area during the study period.
- Satisfactory medical screen, as demonstrated by study screening document normal physical examination and normal screening blood tests
- Group 1: Any flavivirus exposure status; Group 2: No previous flavivirus vaccination (JE, tick borne encephalitis or yellow fever (YF)), no residence in a flavivirus endemic area nor planned travel to a flavivirus endemic area during the period of the study; Group 3: JE vaccine and/or yellow fever vaccine or other proven flavivirus infection within the last 10 years or other proven flavivirus infection (lifetime).
- An efficacious method of contraception must be used during the study for women of childbearing potential.
Exclusion Criteria:
- Use of any investigational or non-registered drug within 5 half-lives of the drug, or 30 days preceding administration of study JE vaccine, whichever is longer; or planned use during the study period.
- Receipt of any investigational biologic agents with mechanisms of action that might affect the immune system, at the discretion of the CI and local PI.
- Administration of immunosuppressants or other immune-modifying drugs within a period of six months before vaccination or at any time during the study period; participants who have received these agents may also be excluded at the discretion of the CI and local PI.
- Any confirmed or suspected immunosuppressive or immunodeficient condition.
- A family history of congenital or hereditary immunodeficiency.
- Any antiviral drug therapy within a period of 5 drug half-lives or 30 days before vaccination, whichever is longer, or at any time during the study period.
- History of significant allergic reactions likely to be exacerbated by any component of the study vaccine, especially allergic disease or reactions to any previous dose of any vaccine.
- History of having received JE vaccine, yellow fever vaccine, tick-borne encephalitis vaccine or experimental flavivirus vaccine (group 2 only).
- Detectable anti Flavivirus neutralizing antibodies in screening tests (group 2 only).
- Acute disease (for example acute infection) at the time of enrolment or vaccination, if symptoms are rated as anything more significant than a mild adverse event. Entry into the study and/or vaccination may be deferred until the illness has resolved for at least one week.
- Acute or chronic, clinically significant in the opinion of the investigator, disease in any organ system, as determined by history, physical examination or laboratory testing.
- Presence of any inflammatory condition that might require immunomodulatory therapy.
- Recent blood donation (inclusion can be delayed under these circumstances; the participant should be enrolled 16 weeks after their last blood donation. Each participant should give no more than 470 ml per 16 weeks, so regular blood donation should be suspended during the study and can re-commence 1 month after the last study sample).
- Current or previous abattoir worker or sheep farmer in Scotland (risk of Louping ill virus exposure; group 2 only).
- Administration of immunoglobulins and/or any blood products within the three months preceding administration of vaccine, or planned administration during the study period.
- Seropositive for HIV.
- Pregnancy or Lactation.
- History of excessive alcohol consumption (>28 units per week), drug abuse or significant psychiatric illness.
- Any other condition or consideration that, in the opinion of the Investigator, would pose a health risk to the participant if they were enrolled in the study, or would otherwise interfere with the evaluation of the study aims (e.g. difficult venesection).
Sites / Locations
- Liverpool University Hospitals NHS Foundation Trust
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Other
Other
Other
Arm Label
Group 1 - Any status
Group 2 - FlaviPrime Naive
Group 3 - Flavivirus Exposed
Arm Description
Up to 3-4 healthy adults
Up to 6-8 healthy adults who have never travelled to a flavivirus endemic area and are negative in screening tests for flavivirus immunity.
Up to 8-10 healthy adults who have had JE vaccine and/or are previously flavivirus exposed, either through receiving yellow fever vaccine up to 5 years before the study, or from being diagnosed with a flavivirus illness (e.g. dengue or Zika).
Outcomes
Primary Outcome Measures
Primary: Plasmablast percentage of total B cells at 7 days post vaccine
Plasmablast percentage of total B cells at 7 days post vaccine Number of plasmablasts sorted by flow cytometry at 7 days post vaccine
Primary: Neutralising antibody titre, measured by 50% of viral plaque reduction at one and two months post vaccine
Neutralising antibody titre, measured by 50% of viral plaque reduction at one and two months post vaccine
Secondary Outcome Measures
Secondary: Number of adverse events occurring in all participants in one month post vaccine
Number of adverse events occurring in all participants in one month post vaccine
Full Information
NCT ID
NCT03920111
First Posted
April 4, 2019
Last Updated
October 31, 2022
Sponsor
University of Liverpool
1. Study Identification
Unique Protocol Identification Number
NCT03920111
Brief Title
Flavivirus Cross-priming Potential of IMOJEV
Acronym
FlaviPrime
Official Title
Flavivirus Cross-priming Potential of Live Attenuated Japanese Encephalitis (JE) Vaccine IMOJEV in Flavivirus naïve and Flavivirus Experienced Participants
Study Type
Interventional
2. Study Status
Record Verification Date
October 2022
Overall Recruitment Status
Completed
Study Start Date
April 16, 2021 (Actual)
Primary Completion Date
December 23, 2021 (Actual)
Study Completion Date
May 11, 2022 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Liverpool
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
There is a pressing need for a better experimental system to understand flavivirus antibody responses, beyond dengue, to make sure the investigators are using current vaccines to greatest effect and to inform the development of next-generation vaccines. This study will use live chimeric JE vaccine IMOJEV® as a tool for flavivirus epitope discovery. This will allow experimental JEV infection using replication competent, live, attenuated virus as a model, in a setting where the flavivirus infection history of humans can be tightly controlled.
Detailed Description
This study will test the hypothesis that in previously flavivirus-exposed individuals, the antibody response is more broadly cross neutralising, and that this will lead to the identification of conserved virion surface epitopes that could be the target of second generation vaccines.
Exploratory Primary Objectives/Specific aims:
To establish a human model system of JEV infection in healthy adult volunteers using live attenuated JE vaccine IMOJEV®.
To sort and sequence individual responding B cells (plasmablasts) after vaccination with IMOJEV®, and to generate human monoclonal antibodies to JEV.
To generate JEV specific human monoclonal antibodies from the sequences derived in (2).
To describe the development, specificity, cross-reactivity and function of the T cell response to IMOJEV®.
To establish a sample bank for future work on cross-reactive and other responses to flaviviruses, flavivirus vaccines and other emergent viruses.
Exploratory Secondary Objectives:
To examine the specificity and cross-reactivity of the antibody response after JE vaccination, using serum and human monoclonal antibodies.
To determine whether there are epitopes which can serve as the target of broadly cross-neutralising antibody responses.
Experimentally the fine specificity and cross-reactivity of the antibody response will be studied by cloning antibodies from plasmablasts (B cells responding to the vaccine) that have been single cell sorted by flow cytometry then sequenced at one week post vaccine. These human monoclonal antibodies will then be mapped on to the surface of the virus particle using established approaches, and tested to look for cross-reactive antibodies. T cell responses to the vaccine will be studied using custom pools of synthetic peptides by ELISpot and flow cytometry.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Japanese Encephalitis
7. Study Design
Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
18 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Group 1 - Any status
Arm Type
Other
Arm Description
Up to 3-4 healthy adults
Arm Title
Group 2 - FlaviPrime Naive
Arm Type
Other
Arm Description
Up to 6-8 healthy adults who have never travelled to a flavivirus endemic area and are negative in screening tests for flavivirus immunity.
Arm Title
Group 3 - Flavivirus Exposed
Arm Type
Other
Arm Description
Up to 8-10 healthy adults who have had JE vaccine and/or are previously flavivirus exposed, either through receiving yellow fever vaccine up to 5 years before the study, or from being diagnosed with a flavivirus illness (e.g. dengue or Zika).
Intervention Type
Biological
Intervention Name(s)
IMOJEV
Intervention Description
live attenuated Japanese encephalitis (JE) vaccine IMOJEV®
Primary Outcome Measure Information:
Title
Primary: Plasmablast percentage of total B cells at 7 days post vaccine
Description
Plasmablast percentage of total B cells at 7 days post vaccine Number of plasmablasts sorted by flow cytometry at 7 days post vaccine
Time Frame
1 week
Title
Primary: Neutralising antibody titre, measured by 50% of viral plaque reduction at one and two months post vaccine
Description
Neutralising antibody titre, measured by 50% of viral plaque reduction at one and two months post vaccine
Time Frame
two months
Secondary Outcome Measure Information:
Title
Secondary: Number of adverse events occurring in all participants in one month post vaccine
Description
Number of adverse events occurring in all participants in one month post vaccine
Time Frame
one month
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
A male or female adult between 18 and 70 years of age at consent.
Written and informed consent obtained from participant and agreement of participant to comply with the requirements of the study
Able to attend regularly to donate study blood samples for the duration of the study (8 weeks), no planned re-location or travel to a flavivirus endemic area during the study period.
Satisfactory medical screen, as demonstrated by study screening document normal physical examination and normal screening blood tests
Group 1: Any flavivirus exposure status; Group 2: No previous flavivirus vaccination (JE, tick borne encephalitis or yellow fever (YF)), no residence in a flavivirus endemic area nor planned travel to a flavivirus endemic area during the period of the study; Group 3: JE vaccine and/or yellow fever vaccine or other proven flavivirus infection within the last 10 years or other proven flavivirus infection (lifetime).
An efficacious method of contraception must be used during the study for women of childbearing potential.
Exclusion Criteria:
Use of any investigational or non-registered drug within 5 half-lives of the drug, or 30 days preceding administration of study JE vaccine, whichever is longer; or planned use during the study period.
Receipt of any investigational biologic agents with mechanisms of action that might affect the immune system, at the discretion of the CI and local PI.
Administration of immunosuppressants or other immune-modifying drugs within a period of six months before vaccination or at any time during the study period; participants who have received these agents may also be excluded at the discretion of the CI and local PI.
Any confirmed or suspected immunosuppressive or immunodeficient condition.
A family history of congenital or hereditary immunodeficiency.
Any antiviral drug therapy within a period of 5 drug half-lives or 30 days before vaccination, whichever is longer, or at any time during the study period.
History of significant allergic reactions likely to be exacerbated by any component of the study vaccine, especially allergic disease or reactions to any previous dose of any vaccine.
History of having received JE vaccine, yellow fever vaccine, tick-borne encephalitis vaccine or experimental flavivirus vaccine (group 2 only).
Detectable anti Flavivirus neutralizing antibodies in screening tests (group 2 only).
Acute disease (for example acute infection) at the time of enrolment or vaccination, if symptoms are rated as anything more significant than a mild adverse event. Entry into the study and/or vaccination may be deferred until the illness has resolved for at least one week.
Acute or chronic, clinically significant in the opinion of the investigator, disease in any organ system, as determined by history, physical examination or laboratory testing.
Presence of any inflammatory condition that might require immunomodulatory therapy.
Recent blood donation (inclusion can be delayed under these circumstances; the participant should be enrolled 16 weeks after their last blood donation. Each participant should give no more than 470 ml per 16 weeks, so regular blood donation should be suspended during the study and can re-commence 1 month after the last study sample).
Current or previous abattoir worker or sheep farmer in Scotland (risk of Louping ill virus exposure; group 2 only).
Administration of immunoglobulins and/or any blood products within the three months preceding administration of vaccine, or planned administration during the study period.
Seropositive for HIV.
Pregnancy or Lactation.
History of excessive alcohol consumption (>28 units per week), drug abuse or significant psychiatric illness.
Any other condition or consideration that, in the opinion of the Investigator, would pose a health risk to the participant if they were enrolled in the study, or would otherwise interfere with the evaluation of the study aims (e.g. difficult venesection).
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Lance Turtle, Dr
Organizational Affiliation
University of Liverpool
Official's Role
Principal Investigator
Facility Information:
Facility Name
Liverpool University Hospitals NHS Foundation Trust
City
Liverpool
ZIP/Postal Code
L7 8XP
Country
United Kingdom
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Flavivirus Cross-priming Potential of IMOJEV
We'll reach out to this number within 24 hrs